Skip to main content

Assessment and improvement of selected technologies to remove or inactivate TSE - causing agents ("prions")

Objective



TSE causing agents ("prions") are extremely difficult to remove or inactivat especially if the biological activity of the matrix (e.g. enzymes, antibodies, plasma or othel biologically derived therapeuticals) must be retained. Nevertheless, some processes havE developed and shown to inactivate prions with high efficacy (e.g. the HAEMOSAFE proce others show potential to remove prions (e.g. reversed phase chromatography, hydrophot interaction chromatography, solvent extraction), but there exist contradictory results in lite as to what dearee. This project will determine the potential of these processes in 2 stages: a) they will be optimised for a number of key biologicals to yield unchanged biologic active products in high yield and purity b) the prion removal or inactivation will be demonstrated in spiking experiments. Thf be both IN VIVO and IN VITRO tests done in parallel in order to evaluate the pc of the newly emerging in vitro tests (DELFIA, western blot).

Funding Scheme

EAW - Exploratory awards

Coordinator

HAEMOSAN Erzuegung Pharmazeutischer Grundstoffe GesmbH.
Address
20,Kahngasse
8045 Graz
Austria

Participants (1)

Q-ONE Biotech Ltd
United Kingdom
Address
West Of Scotland Science Park
G20 0 XA Glasgow